Form D · Pharmaceuticals

NUVO RESEARCH INC

Mississauga, A6 · CIK 0001371679

Offering snapshot reported May 27, 2011 · SEC filing

Reported sold: $0
Investors reported: 44
Minimum accepted: $0
First sale: May 12, 2011

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
May 27, 2011	Initial	$0	No comparison	44	SEC filing
Jul 27, 2007	Paper	Not reported	No comparison	Not reported	SEC filing
Jul 28, 2006	Paper	Not reported	No comparison	Not reported	SEC filing

Offering details

Securities: Other
Exemptions: 06
Duration over one year: No
Business combination: Yes

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-160481

Pursuant to the acquisition of ZARS Pharma Inc., Nuvo Research Inc. issued to certain shareholders of ZARS 80,124,881 common shares for no cash consideration on 05/12/11.

Common Shares

Source: Form D, filed May 27, 2011. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Daniel N. Chicoine	Director, Executive
David A. Copeland	Director
Anthony E. Dobranowski	Director
Bradley S. Galer	Executive
Henrich R.K. Guntermann	Director, Executive
Stephen L. Lemieux	Executive
John C. London	Director, Executive
Katina K. Loucaides	Executive
Jacques Messier	Director
James L. Moulds	Executive
Theodore Stanley	Director
Klaus Von Lindeiner	Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:

7560 Airport Road Unit 10
Mississauga, A6, L4T 4H4